The BioMedWire Podcast

The latest episode features Rob Etherington, President and CEO of Clene Inc. (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases.

To begin the interview, Etherington discussed Clene’s mission, including its novel approach to the treatment of diseases such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS).

“Clene Inc. is focused entirely on improving mitochondrial health and protecting neuron function. This is a very important thing we can do to treat neurodegenerative diseases such as ALS, MS and Parkinson's,” he said. “This is particularly topical today, because the World Health Organization is predicting that neurodegenerative diseases will become the second-most prevalent cause of death within the next two decades. We're pioneering a very unique approach: the use of an oral suspension that patients can drink to treat the deficits that they might have if afflicted with one of these devastating neurodegenerative diseases.”